Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 95
Filtrar
1.
Aging (Albany NY) ; 16(10): 8484-8496, 2024 May 20.
Artículo en Inglés | MEDLINE | ID: mdl-38771126

RESUMEN

AIM: This study determines to validate the mechanism of Shexiang Tongxin dropping pill (STDP) in attenuating coronary microembolization (CME) induced myocardial injury. METHODS: CME rat models were established and underwent corresponding treating. Gene chip analysis was performed in rat myocardial tissues for GO and KEGG enrichment analysis. The differentially expressed genes were detected by qRT-PCR. H&E staining and ELISA were used for pathological analysis and detection of troponin (cTnI) and Creatine Kinase Isoenzyme (CK-MB). Lipopolysaccharide (LPS) treated primary cardiomyocytes were used to mimic inflammatory in vitro models. Cell viability and apoptosis of cardiomyocytes were determined by MTT and flow cytometry. The expressions of inflammatory cytokines, apoptotic proteins and proteins related to the STAT3 signal pathway were detected by western blot. APOC1 mRNA expression was detected by qRT-PCR. Immunofluorescence (IF) was used for subcellular localization of p-STAT3 and the binding of APOC1 with STAT3 was verified using Co-IP. RESULTS: STDP can attenuate myocardial injury in CME rat models, and lead to decreased expression of APOC1 and suppressed STAT3 signal pathway. In vitro models found STDP can suppress the cell viability and cell apoptosis of primary cardiomyocytes, in addition to suppressing the secretions of IL-6, IL-1ß and TNF-α, while the protective effect of STDP can be reversed by overexpression of APOC1. Co-IP found that APOC1 can bind STAT3 directly. APOC1 can increase p-STAT3 expression in the nucleus to activate the STAT3 signal pathway. CONCLUSIONS: STDP can suppress APOC1 and STAT3 signal pathway to inhibit inflammation and cell apoptosis of cardiomyocytes. APOC1 may be one of the key regulatory factors in CME-induced myocardial injury.


Asunto(s)
Apoptosis , Medicamentos Herbarios Chinos , Miocitos Cardíacos , Factor de Transcripción STAT3 , Transducción de Señal , Animales , Medicamentos Herbarios Chinos/farmacología , Medicamentos Herbarios Chinos/uso terapéutico , Factor de Transcripción STAT3/metabolismo , Transducción de Señal/efectos de los fármacos , Ratas , Miocitos Cardíacos/metabolismo , Miocitos Cardíacos/efectos de los fármacos , Miocitos Cardíacos/patología , Apoptosis/efectos de los fármacos , Masculino , Regulación hacia Abajo/efectos de los fármacos , Ratas Sprague-Dawley , Modelos Animales de Enfermedad , Embolia/metabolismo , Apolipoproteína C-III/metabolismo , Apolipoproteína C-III/genética
2.
Ann Bot ; 129(5): 555-566, 2022 04 13.
Artículo en Inglés | MEDLINE | ID: mdl-35141741

RESUMEN

BACKGROUND AND AIMS: Foliar water uptake has recently been suggested as a possible mechanism for the restoration of hydraulically dysfunctional xylem vessels. In this paper we used a combination of ecophysiological measurements, X-ray microcomputed tomography and cryo-scanning electron microscopy during a drought treatment to fully evaluate this hypothesis. KEY RESULTS: Based on an assessment of these methods in beech (Fagus sylvatica L.) seedlings we were able to (1) confirm an increase in the amount of hydraulically redistributed water absorbed by leaves when the soil water potential decreased, and (2) locate this redistributed water in hydraulically active vessels in the stem. However, (3) no embolism repair was observed irrespective of the organ under investigation (i.e. stem, petiole or leaf) or the intensity of drought. CONCLUSIONS: Our data provide evidence for a hydraulic pathway from the leaf surface to the stem xylem following a water potential gradient, but this pathway exists only in functional vessels and does not play a role in embolism repair for beech.


Asunto(s)
Embolia , Fagus , Sequías , Embolia/metabolismo , Hojas de la Planta/fisiología , Agua/metabolismo , Microtomografía por Rayos X , Xilema/fisiología
3.
Pharmacol Res Perspect ; 9(1): e00714, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33507583

RESUMEN

Coronary microembolization (CME)-induced inflammation and cardiomyocyte apoptosis are two key factors contributing to CME-induced myocardial dysfunction. High-mobility group box-1 (HMGB1) plays essential role in progression of CME-induced injury and inhibition of HMGB1 has been shown to be protective. In present study, the potential effects of glycyrrhizin, a HMGB1 inhibitor, on CME-induced myocardial dysfunction are evaluated. Using a rat model of CME, we administrated glycyrrhizin in rats prior to CME induction. The level of HMGB1, TNF-α, iNOS, IL-6, IL-1ß, cleaved caspase-3, Bax, and Bcl-2 were measured. The serum level of cardiac troponin I, creatine kinase, was detected. The cardiac function and cardiomyocyte apoptosis were evaluated. The activation of TLR4/NF-κB signaling pathway was analyzed. Glycyrrhizin prevented CME-induced production of HMGB1, TNF-α, iNOS, IL-6, and IL-1ß. Glycyrrhizin inhibited CME-induced cardiomyocyte apoptosis and the expression of cleaved caspase-3 and Bax, while enhanced the expression of Bcl-2. Glycyrrhizin decreased cardiac troponin I and creatine kinase levels and improved cardiac function. Glycyrrhizin prevented the activation of HMGB1/TLR4/NF-κB signaling pathway. Glycyrrhizin ameliorated myocardial dysfunction in CME rats by preventing inflammation and apoptosis of cardiomyocytes.


Asunto(s)
Antiinflamatorios/uso terapéutico , Cardiotónicos/uso terapéutico , Embolia/tratamiento farmacológico , Ácido Glicirrínico/uso terapéutico , Proteína HMGB1/antagonistas & inhibidores , Disfunción Ventricular Izquierda/tratamiento farmacológico , Animales , Antiinflamatorios/farmacología , Apoptosis/efectos de los fármacos , Gasto Cardíaco/efectos de los fármacos , Cardiotónicos/farmacología , Vasos Coronarios , Citocinas/genética , Citocinas/metabolismo , Embolia/genética , Embolia/metabolismo , Ácido Glicirrínico/farmacología , Proteína HMGB1/sangre , Proteína HMGB1/genética , Proteína HMGB1/metabolismo , Masculino , Miocardio/metabolismo , Miocitos Cardíacos/efectos de los fármacos , FN-kappa B/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacos , Receptor Toll-Like 4/metabolismo , Disfunción Ventricular Izquierda/genética , Disfunción Ventricular Izquierda/metabolismo
4.
Pharmacol Res Perspect ; 9(1): e00699, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33448699

RESUMEN

Cardiomyocyte apoptosis is a key factor in the deterioration of cardiac function after coronary microembolization (CME). Nicorandil (NIC) affects myocardial injury, which may be related to the inhibition of apoptosis. However, the specific mechanism of cardioprotection has not been elucidated. Therefore, we analyzed the impact of NIC on cardiac function in rats subjected to CME and its effect on the high-temperature requirement peptidase 2/X-linked inhibitor of apoptosis protein/poly ADP-ribose polymerase (HtrA2/XIAP/PARP) pathway. Sprague Dawley rats were divided into four groups: Sham, CME, CME + NIC, and CME + UCF. Echocardiography was performed 9 hours after CME. Myocardial injury markers were evaluated in blood samples, and the heart tissue was collected for hematoxylin-eosin staining, hematoxylin basic fuchsin picric acid staining staining, TdT-mediated DUTP nick end labeling (TUNEL) staining, Western blot analysis of the HtrA2/XIAP/PARP pathway, and transmission electron microscopy. NIC ameliorated cardiac dysfunctioncaused by CME and reduced serum levels of CK-MB and LDH. In addition, NIC decreased myocardial microinfarct size and apoptotic index. NIC reduced the Bax/Bcl-2 ratio, levels of cleaved caspase 3/9, cytoplasmic HtrA2, and cleaved PARP, and increased the level of XIAP. The effects of NIC were similar to those of the HtrA2 inhibitor, UCF101. This study demonstrated that NIC reduces CME-induced myocardial injury, reduces mitochondrial damage, and improves myocardial function. The reduction in cardiomyocyte apoptosis by NIC may be mediated by the HtrA2/XIAP/PARP signaling pathway.


Asunto(s)
Antiarrítmicos/uso terapéutico , Embolia/tratamiento farmacológico , Infarto del Miocardio/tratamiento farmacológico , Nicorandil/uso terapéutico , Animales , Antiarrítmicos/farmacología , Aorta/patología , Apoptosis/efectos de los fármacos , Proteínas Reguladoras de la Apoptosis/metabolismo , Embolia/metabolismo , Embolia/patología , Femenino , Proteínas Inhibidoras de la Apoptosis/metabolismo , Masculino , Infarto del Miocardio/metabolismo , Infarto del Miocardio/patología , Miocardio/metabolismo , Miocardio/patología , Miocitos Cardíacos/efectos de los fármacos , Proteínas del Tejido Nervioso/metabolismo , Nicorandil/farmacología , Inhibidores de Poli(ADP-Ribosa) Polimerasas/metabolismo , Ratas Sprague-Dawley , Factores de Empalme Serina-Arginina/metabolismo , Transducción de Señal/efectos de los fármacos
5.
Cardiol Rev ; 29(1): 43-47, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-32947478

RESUMEN

The novel coronavirus (severe acute respiratory syndrome CoV-2 [SARS-CoV-2]), also known as COVID-19, is a single-stranded enveloped RNA virus that created a Public Health Emergency of International Concern in January 2020, with a global case burden of over 15 million in just 7 months. Infected patients develop a wide range of clinical manifestations-typically presenting with fever, cough, myalgia, and fatigue. Severely ill patients may fall victim to acute respiratory distress syndrome, acute heart injuries, neurological manifestations, or complications due to secondary infections. These critically ill patients are also found to have disrupted coagulation function, predisposing them to consumptive coagulopathies, and both venous and thromboembolic complications. Common laboratory findings include thrombocytopenia, elevated D-dimer, fibrin degradation products, and fibrinogen, all of which have been associated with greater disease severity. Many cases of pulmonary embolism have been noted, along with deep vein thrombosis, ischemic stroke, myocardial infarction, and systemic arterial embolism. The pathogenesis of coronavirus has not been completely elucidated, but the virus is known to cause excessive inflammation, endothelial injury, hypoxia, and disseminated intravascular coagulation, all of which contribute to thrombosis formation. These patients are also faced with prolonged immobilization while staying in the hospital or intensive care unit. It is important to have a high degree of suspicion for thrombotic complications as patients may rapidly deteriorate in severe cases. Evidence suggests that prophylaxis with anticoagulation may lead to a lower risk of mortality, although it does not eliminate the possibility. The risks and benefits of anticoagulation treatment should be considered in each case. Patients should be regularly evaluated for bleeding risks and thrombotic complications.


Asunto(s)
Trastornos de la Coagulación Sanguínea/sangre , COVID-19/sangre , Embolia/sangre , Trombosis/sangre , Anticoagulantes/uso terapéutico , Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Trastornos de la Coagulación Sanguínea/etiología , Trastornos de la Coagulación Sanguínea/metabolismo , COVID-19/complicaciones , COVID-19/metabolismo , Síndrome de Liberación de Citoquinas/sangre , Síndrome de Liberación de Citoquinas/complicaciones , Síndrome de Liberación de Citoquinas/metabolismo , Coagulación Intravascular Diseminada/sangre , Coagulación Intravascular Diseminada/etiología , Coagulación Intravascular Diseminada/metabolismo , Coagulación Intravascular Diseminada/prevención & control , Embolia/etiología , Embolia/metabolismo , Embolia/prevención & control , Endotelio Vascular/metabolismo , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Fibrinógeno/metabolismo , Humanos , Hipoxia/sangre , Hipoxia/etiología , Hipoxia/metabolismo , Inmovilización , Inflamación/sangre , Inflamación/etiología , Inflamación/metabolismo , Accidente Cerebrovascular Isquémico/sangre , Accidente Cerebrovascular Isquémico/etiología , Accidente Cerebrovascular Isquémico/metabolismo , Accidente Cerebrovascular Isquémico/prevención & control , Infarto del Miocardio/sangre , Infarto del Miocardio/etiología , Infarto del Miocardio/metabolismo , Infarto del Miocardio/prevención & control , Guías de Práctica Clínica como Asunto , Embolia Pulmonar/sangre , Embolia Pulmonar/etiología , Embolia Pulmonar/metabolismo , Embolia Pulmonar/prevención & control , Índice de Severidad de la Enfermedad , Trombocitopenia/sangre , Trombocitopenia/etiología , Trombosis/etiología , Trombosis/metabolismo , Trombosis/prevención & control , Trombosis de la Vena/sangre , Trombosis de la Vena/etiología , Trombosis de la Vena/metabolismo , Trombosis de la Vena/prevención & control
6.
J Am Heart Assoc ; 9(24): e018984, 2020 12 15.
Artículo en Inglés | MEDLINE | ID: mdl-33292046

RESUMEN

Background To explore the pathophysiological features of ischemic stroke in patients with atrial fibrillation (AF), we evaluated the association between 268 plasma proteins and subsequent ischemic stroke in 2 large AF cohorts receiving oral anticoagulation. Methods and Results A case-cohort sample of patients with AF from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, including 282 cases with ischemic stroke or systemic embolism and a random sample of 4124 without these events, during 1.9 years of follow-up was used for identification. Validation was provided by a similar case-cohort sample of patients with AF from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial, including 149 cases with ischemic stroke/systemic embolism and a random sample of 1062 without these events. In plasma obtained before randomization, 268 unique biomarkers were measured with OLINK proximity extension assay panels (CVD II, CVD III, and Inflammation) and conventional immunoassays. The association between biomarkers and outcomes was evaluated by random survival forest and adjusted Cox regression. According to random survival forest or Cox regression analyses, the biomarkers most strongly and consistently associated with ischemic stroke/systemic embolism were matrix metalloproteinase-9, NT-proBNP (N-terminal pro-B-type natriuretic peptide), osteopontin, sortilin, soluble suppression of tumorigenesis 2, and trefoil factor-3. The corresponding hazard ratios (95% CIs) for an interquartile difference were as follows: 1.18 (1.00-1.38), 1.55 (1.28-1.88), 1.28 (1.07-1.53), 1.19 (1.02-1.39), 1.23 (1.05-1.45), and 1.19 (0.97-1.45), respectively. Conclusions In patients with AF, of 268 unique biomarkers, the 6 biomarkers most strongly associated with subsequent ischemic stroke/systemic embolism represent fibrosis/remodeling (matrix metalloproteinase-9 and soluble suppression of tumorigenesis 2), cardiac dysfunction (NT-proBNP), vascular calcification (osteopontin), metabolism (sortilin), and mucosal integrity/ischemia (trefoil factor-3). Registration URL: https://www.clinicaltrials.gov. Unique Identifiers: NCT00412984 and NCT00262600.


Asunto(s)
Fibrilación Atrial/complicaciones , Biomarcadores/sangre , Accidente Cerebrovascular Isquémico/diagnóstico , Accidente Cerebrovascular Isquémico/metabolismo , Proteínas Adaptadoras del Transporte Vesicular/sangre , Anciano , Anciano de 80 o más Años , Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Embolia/metabolismo , Inhibidores del Factor Xa/uso terapéutico , Femenino , Humanos , Proteína 1 Similar al Receptor de Interleucina-1/metabolismo , Accidente Cerebrovascular Isquémico/mortalidad , Accidente Cerebrovascular Isquémico/fisiopatología , Masculino , Metaloproteinasa 9 de la Matriz/sangre , Persona de Mediana Edad , Péptido Natriurético Encefálico/sangre , Osteopontina/sangre , Evaluación del Resultado de la Atención al Paciente , Fragmentos de Péptidos/sangre , Pirazoles/uso terapéutico , Piridonas/uso terapéutico , Accidente Cerebrovascular/prevención & control , Tromboembolia/prevención & control , Factor Trefoil-3/sangre
7.
Circulation ; 142(20): 1974-1988, 2020 11 17.
Artículo en Inglés | MEDLINE | ID: mdl-33196311

RESUMEN

Balancing benefits and risks is a complex task that poses a major challenge, both to the approval of new medicines and devices by regulatory authorities and in therapeutic decision-making in practice. Several analysis methods and visualization tools have been developed to help evaluate and communicate whether the benefit-risk profile is favorable or unfavorable. In this White Paper, we describe approaches to benefit-risk assessment using qualitative approaches such as the Benefit Risk Action Team framework developed by the Pharmaceutical Research and Manufacturers of America, and the Benefit-Risk Framework developed by the United States Food and Drug Administration; and quantitative approaches such as the numbers needed to treat for benefit and harm, the benefit-risk ratio, and Incremental Net Benefit. We give illustrative examples of benefit-risk evaluations using 4 treatment interventions including sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes; a direct antithrombin agent, dabigatran, for reducing stroke and systemic embolism in patients with nonvalvular atrial fibrillation; transcatheter aortic valve replacement in patients with symptomatic severe aortic valve stenosis; and antiplatelet agents vorapaxar and prasugrel for reducing cardiovascular events in patients at high cardiovascular risk. Regular applications of structured benefit-risk assessment, whether qualitative, quantitative, or both, enabled by easy-to-understand graphical presentations that capture uncertainties around the benefit-risk metric, may aid shared decision-making and enhance transparency of those decisions.


Asunto(s)
Fibrilación Atrial/tratamiento farmacológico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Descubrimiento de Drogas , Embolia/prevención & control , Equipos y Suministros , Fibrinolíticos/uso terapéutico , Hipoglucemiantes/uso terapéutico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Accidente Cerebrovascular/prevención & control , Fibrilación Atrial/complicaciones , Fibrilación Atrial/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Embolia/etiología , Embolia/metabolismo , Humanos , Proteínas de Transporte de Sodio-Glucosa/antagonistas & inhibidores , Proteínas de Transporte de Sodio-Glucosa/metabolismo , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/metabolismo , Estados Unidos , United States Food and Drug Administration
8.
Sci Rep ; 9(1): 18575, 2019 12 09.
Artículo en Inglés | MEDLINE | ID: mdl-31819089

RESUMEN

Hepatocellular Carcinoma (HCC) is one of the most lethal cancers with a high mortality and recurrence rate. Circulating tumor cell (CTC) detection offers various opportunities to advance early detection and monitoring of HCC tumors which is crucial for improving patient outcome. We developed and optimized a novel Labyrinth microfluidic device to efficiently isolate CTCs from peripheral blood of HCC patients. CTCs were identified in 88.1% of the HCC patients over different tumor stages. The CTC positivity rate was significantly higher in patients with more advanced HCC stages. In addition, 71.4% of the HCC patients demonstrated CTCs positive for cancer stem cell marker, CD44, suggesting that the major population of CTCs could possess stemness properties to facilitate tumor cell survival and dissemination. Furthermore, 55% of the patients had the presence of circulating tumor microemboli (CTM) which also correlated with advanced HCC stage, indicating the association of CTM with tumor progression. Our results show effective CTC capture from HCC patients, presenting a new method for future noninvasive screening and surveillance strategies. Importantly, the detection of CTCs with stemness markers and CTM provides unique insights into the biology of CTCs and their mechanisms influencing metastasis, recurrence and therapeutic resistance.


Asunto(s)
Carcinoma Hepatocelular/sangre , Embolia/metabolismo , Dispositivos Laboratorio en un Chip , Neoplasias Hepáticas/sangre , Células Neoplásicas Circulantes/metabolismo , Células Madre Neoplásicas/citología , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor , Progresión de la Enfermedad , Resistencia a Antineoplásicos , Células Hep G2 , Humanos , Microfluídica , Microscopía Fluorescente , Persona de Mediana Edad , Metástasis de la Neoplasia , Recurrencia Local de Neoplasia , Investigación Biomédica Traslacional , Resultado del Tratamiento
9.
J Cell Biochem ; 120(6): 10756-10766, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30652345

RESUMEN

Coronary microembolization (CME) occurs when atherosclerotic plaque debris is detached during the treatment of acute coronary syndrome with Percutaneous Coronary Intervention (PCI). The complications of distal microvascular embolism, including local myocardial inflammation, are the main causes of myocardial damage and are a strong predictor of poor long-term prognosis and major cardiac adverse events. microRNAs (miRNAs) are involved in the pathophysiological processes of cardiovascular inflammatory diseases. Dysregulation of microRNA (miR)-26a-5p, in particular, is associated with a variety of cardiovascular diseases. However, the role of miR-26a-5p in CME-induced myocardial injury is unclear. In this study, we developed an animal model of CME by injecting microembolic balls into the left ventricle of rats and found that miR-26a-5p expression decreased in myocardial tissue in response. Using a miR-26a-5p mimic, echocardiography, hematoxylin-eosin staining, and Western blot analysis we found that the diminished cardiac function and myocardial inflammation induced by CME is alleviated by miR-26a-5p overexpression. Furthermore, our results show that inhibitors of miR-26a-5p have the opposite effect. In addition, in vitro experiments using real-time PCR, Western blot analysis, and a dual luciferase reporter gene show that HMGA1 is a target gene of miR-26a-5p. Thus, overexpression of miR-26a-5p could be a novel therapy to improve CME-induced myocardial damage.


Asunto(s)
Vasos Coronarios/metabolismo , Embolia/genética , Proteína HMGA1a/genética , MicroARNs/genética , Miocardio/metabolismo , Animales , Antagomirs/genética , Antagomirs/metabolismo , Gasto Cardíaco , Vasos Coronarios/diagnóstico por imagen , Vasos Coronarios/patología , Modelos Animales de Enfermedad , Ecocardiografía , Embolia/diagnóstico por imagen , Embolia/etiología , Embolia/metabolismo , Femenino , Regulación de la Expresión Génica , Proteína HMGA1a/metabolismo , Masculino , MicroARNs/agonistas , MicroARNs/antagonistas & inhibidores , MicroARNs/metabolismo , Miocardio/patología , Oligorribonucleótidos/genética , Oligorribonucleótidos/metabolismo , Intervención Coronaria Percutánea/efectos adversos , Ratas , Ratas Sprague-Dawley , Transducción de Señal , Volumen Sistólico , Troponina I/genética , Troponina I/metabolismo , Función Ventricular Izquierda
10.
Naunyn Schmiedebergs Arch Pharmacol ; 392(3): 341-348, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30506291

RESUMEN

Coronary microembolization (CME) caused by physical obstruction in coronary microcirculation induces myocardial apoptosis and cardiac dysfunction, and it was reported that the inactivation of the Nrf2/HO-1 signaling was involved in this process. Astaxanthin (AST) is a reddish pigment that belongs to keto-carotenoids. It is also a potent antioxidant and has been reported to activate Nrf2/HO-1 signaling in vein endothelial cells. However, it is still unknown whether AST is able to activate Nrf2/HO-1 signaling pathway to protect cardiac functions from CME in vivo. To address this question, rats were orally administrated with AST or AST plus Zinc protoporphyrin IX (ZnPP, a HO-1 inhibitor), followed by CME modeling operation. Then, cardiac function was evaluated by echocardiographic measurement. Myocardial infarction was measured by HBFP staining, and apoptosis was assessed by TUNEL staining. The protein levels and mRNA expressions of Bax and Bcl-2 were measured by Western blot and qRT-PCR, respectively. ELISA was performed to measure the activity of enzymes related to oxidative stress. AST pretreatment dramatically attenuated CME-induced cardiac dysfunction, myocardial infarction, and cardiomyocyte apoptosis. Mechanistically, AST suppressed CME-induced oxidative stress by re-activating Nrf2/HO-1 signaling. HO-1 inhibitor ZnPP completely eliminated the benefits of AST in CEM, supporting the critical role of Nrf2/HO-1 signaling in mediating the cardioprotective function of AST in CME. Conclusion: AST suppresses oxidative stress via activating Nrf2/HO-1 pathway and thus prevents CME-induced cardiomyocyte apoptosis and ameliorates cardiac dysfunction in rats.


Asunto(s)
Antioxidantes/farmacología , Embolia/metabolismo , Hemo Oxigenasa (Desciclizante)/metabolismo , Infarto del Miocardio/metabolismo , Miocitos Cardíacos/efectos de los fármacos , Factor 2 Relacionado con NF-E2/metabolismo , Animales , Apoptosis/efectos de los fármacos , Circulación Coronaria , Vasos Coronarios , Embolia/complicaciones , Embolia/fisiopatología , Microcirculación , Infarto del Miocardio/etiología , Infarto del Miocardio/fisiopatología , Miocitos Cardíacos/metabolismo , Estrés Oxidativo/efectos de los fármacos , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacos , Xantófilas/farmacología
11.
PLoS One ; 13(10): e0204838, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30273382

RESUMEN

The aim of this study was to evaluate the diagnostic value of the Score for the Targeting of Atrial Fibrillation (STAF) in combination with the serum D-dimer (DD) levels in cardioembolism(CE).This study was a retrospective case-onlystudy, consecutively including patients with acute ischemic stroke. All patients were evaluated following the STAF scoring criteria and were classified according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) etiology classification criteria. A total of 317 patients were enrolled, including 37 CE cases (11.67%). STAF ≥5 showed a sensitivity of 89% and a specificity of 91% for the diagnosis of CE, whereas DD >791.30 ng/mL had a sensitivity of 58% and a specificity of 78%. When the STAF was used in combination with the DD level, the sensitivity was 95%, and the specificity was 100%.STAF score is an excellent tool for the diagnosis of CE when combined with DD, and can facilitate the etiological classification of acute ischemic stroke.


Asunto(s)
Fibrilación Atrial/diagnóstico , Embolia/diagnóstico , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Infarto del Miocardio/etiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Fibrilación Atrial/metabolismo , Embolia/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Sensibilidad y Especificidad , Adulto Joven
12.
Biomed Pharmacother ; 106: 776-784, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29990871

RESUMEN

Coronary microembolization (CME) is a common complication during the treatment of acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). Nicorandil can be used to prevent myocardial injury after PCI to reduce the incidence of coronary no-reflow and slow flow, and play a role in myocardial protection, suggesting that its mechanism may be related to the inhibition of CME-induced inflammation of cardiomyocytes. However, the specific mechanism remains unclear. This study investigated the myocardial protective effects of nicorandil pretreatment on CME-induced myocardial injury and the specific mechanism of its inhibition of myocardial inflammation. An CME rat model exhibited CME-induced myocardial inflammation and the elevation of serum tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-1ß based on echocardiography, myocardial enzyme detection, hematoxylin and eosin (HE) and hematoxylin-basic fuchsin-picric acid (HBFP) stainings, ELISA, quantitative real-time PCR, and western blotting. Nicorandil treatment seven days before CME induction effectively inhibited myocardial inflammation, ameliorated myocardial injury, and improved cardiac function, mainly by inhibiting Toll-like receptor 4 (TLR4)-mediated myeloid differentiation primary response protein 88 (MyD88)-dependent nuclear factor-kappa B (NF-κB) signaling. Rat neonatal cardiomyocyte experiments further confirmed that nicorandil ameliorated lipopolysaccharide (LPS)-induced myocardial inflammation and improved cardiomyocyte survival. The specific mechanisms mainly involved the inhibition of TLR4/MyD88/NF-κB signaling and the reduction of the inflammatory cytokines TNF-α and IL-1ß released from cardiomyocytes. In summary, nicorandil significantly protected cardiomyocytes from CME-induced myocardial injury mainly by inhibiting TLR4/MyD88/NF-κB signaling, thereby reducing the onset of CME-induced myocardial inflammation. This could be one of the important mechanisms for reducing postoperative myocardial injury via PCI-preoperative prophylactic treatment with nicorandil.


Asunto(s)
Antiinflamatorios/farmacología , Estenosis Coronaria/tratamiento farmacológico , Embolia/tratamiento farmacológico , Factor 88 de Diferenciación Mieloide/metabolismo , Infarto del Miocardio/prevención & control , Miocarditis/prevención & control , Miocitos Cardíacos/efectos de los fármacos , FN-kappa B/metabolismo , Nicorandil/farmacología , Receptor Toll-Like 4/metabolismo , Disfunción Ventricular Izquierda/prevención & control , Animales , Supervivencia Celular , Estenosis Coronaria/etiología , Estenosis Coronaria/metabolismo , Estenosis Coronaria/patología , Citoprotección , Modelos Animales de Enfermedad , Embolia/etiología , Embolia/metabolismo , Embolia/patología , Mediadores de Inflamación/sangre , Interleucina-1beta/sangre , Lipopolisacáridos/farmacología , Masculino , Microesferas , Infarto del Miocardio/etiología , Infarto del Miocardio/metabolismo , Infarto del Miocardio/patología , Miocarditis/etiología , Miocarditis/metabolismo , Miocarditis/patología , Miocitos Cardíacos/metabolismo , Miocitos Cardíacos/patología , Ratas Sprague-Dawley , Transducción de Señal , Volumen Sistólico/efectos de los fármacos , Factor de Necrosis Tumoral alfa/sangre , Disfunción Ventricular Izquierda/etiología , Disfunción Ventricular Izquierda/metabolismo , Disfunción Ventricular Izquierda/fisiopatología , Función Ventricular Izquierda/efectos de los fármacos
13.
Cell Physiol Biochem ; 47(4): 1497-1508, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29940584

RESUMEN

BACKGROUND/AIMS: Coronary microembolization (CME) is a common complication of acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI); Myocardial inflammation, caused by CME, is the main cause of cardiac injury. TLR4/MyD88/NF-κB signaling plays an important role in the development of myocardial inflammation, but its effects on CME remain unclear. To assess the cardiac protective effects of TAK-242 (TLR4 specific inhibitor) on CME-induced myocardial injury, and explore the underlying mechanism. METHODS: Cardiac function, serum c-troponin I level, microinfarct were examined by cardiac ultrasound, myocardial enzyme assessment, HBFP staining. The levels of TLR4/MyD88/NF-κB signaling and NLRP3 inflammasome pathway were detected by ELISA, qRT-PCR and western blot. RESULTS: The results showed inflammatory responses in the myocardium after CME, with increased expression levels of pro-inflammatory factors TNF-α, IL-1ß and IL-18. Meanwhile, TLR4/MyD88/NF-κB signaling and the NLRP3 inflammasome were involved in the inflammatory process. TAK-242 administration before CME effectively inhibited the inflammatory response in the rat myocardium after CME and reduced myocardial injury, mainly by inhibiting TLR4/ MyD88/NF-κB signaling and reducing NLRP3 inflammasome activation. In addition, in vitro assays with neonatal rat cardiomyocytes further confirmed that TLR4/MyD88/NF-κB signaling was significantly activated in the inflammatory response of LPS-induced cardiomyocytes, via activation of the NLRP3 inflammasome. Inhibition of TLR4/MyD88/NF-κB signaling resulted in increased survival of cardiomyocytes mainly by reducing the release of inflammatory cytokines and decreasing NLRP3 inflammasome activation. CONCLUSIONS: TLR4/MyD88/NF-κB signaling participates in the inflammatory response of the myocardium after CME, activating the NLRP3 inflammasome, promoting the inflammatory cascade, and aggravating myocardial injury. Blocking TLR4/MyD88/NF-κB signaling may help reduce myocardial injury and improve cardiac function after CME.


Asunto(s)
Síndrome Coronario Agudo/metabolismo , Embolia/metabolismo , Inflamasomas/metabolismo , Factor 88 de Diferenciación Mieloide/metabolismo , Miocardio/metabolismo , FN-kappa B/metabolismo , Transducción de Señal , Receptor Toll-Like 4/metabolismo , Síndrome Coronario Agudo/etiología , Síndrome Coronario Agudo/patología , Animales , Modelos Animales de Enfermedad , Embolia/complicaciones , Embolia/patología , Masculino , Miocardio/patología , Proteína con Dominio Pirina 3 de la Familia NLR , Ratas , Ratas Sprague-Dawley
14.
Clin Nucl Med ; 43(1): 33-35, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-29076902

RESUMEN

A middle-aged woman underwent Tc-sestamibi parathyroid scintigraphy because of parathyroid disease, and a focal pulmonary uptake of Tc-sestamibi was incidentally found on both planar and SPECT/CT images without corresponding pulmonary abnormality on the CT images. After 10 days, a subsequent parathyroid scintigraphy revealed no pulmonary accumulation. Therefore, the pulmonary intense Tc-sestamibi focus that once appeared in the first scan might be an artifact of iatrogenic microembolism from injection site.


Asunto(s)
Artefactos , Embolia/etiología , Pulmón/metabolismo , Glándulas Paratiroides/diagnóstico por imagen , Tomografía Computarizada por Tomografía Computarizada de Emisión de Fotón Único , Tecnecio Tc 99m Sestamibi/metabolismo , Transporte Biológico , Embolia/metabolismo , Femenino , Humanos , Inyecciones , Persona de Mediana Edad , Glándulas Paratiroides/metabolismo , Neoplasias de las Paratiroides/complicaciones , Neoplasias de las Paratiroides/diagnóstico por imagen , Tecnecio Tc 99m Sestamibi/administración & dosificación
15.
BMC Cardiovasc Disord ; 17(1): 272, 2017 Oct 24.
Artículo en Inglés | MEDLINE | ID: mdl-29065851

RESUMEN

BACKGROUND: Myocardial apoptosis is closely related to myocardial injury caused by coronary microembolization (CME).Nuclear factor erythroid 2-like (Nrf2) has been taken into account as an inhibitor of apoptosis in various tissues. Thus, this research aims to investigate which part Nrf2/HO-1 signaling pathway plays in myocardial apoptosis process following the effect of CME on rats. METHODS: Separate 40 rats then form them into a group of shame, a group of CME, a group of CME plus AAV-Nrf2(AAV-Nrf2 (CME) group) and a group of CME plus AAV-control (AAV-control (CME) group) stochastically and averagely. Rat CME was established by injecting into the left ventricular chamber, with or without pretreatment of adeno-associated virus Nrf2 (AAV-Nrf2). Echocardiological measurements, using Terminal-deoxynucleoitidyl Transferase Mediated Nick End Labeling (TUNEL) to stain, conducting Quantitative PCR in real time (RT-PCR) as well as Western blotting to evaluate the impacts of them functionally, morphologically and molecularly in CME. RESULTS: Nrf2 decreased in cardiomyocytes after CME. Upregulation of Nrf2 inside an organism through AAV connect to improving the function of heart as well as attenuating myocardial apoptosis, following the restrain of proapoptotic mRNAs and proteins like caspase-3, caspase-9 and bax expressing as well as the increase of antiapoptotic mRNA and proteins like HO-1 and bcl-2 expressing. CONCLUSION: Activation of Nrf2/HO-1 pathway can improve CME-induced cardiac dysfunction effectively and also reduce the myocardial apoptosis.


Asunto(s)
Apoptosis , Estenosis Coronaria , Embolia , Hemo Oxigenasa (Desciclizante) , Miocitos Cardíacos , Factor 2 Relacionado con NF-E2 , Animales , Ratas , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Estenosis Coronaria/metabolismo , Dependovirus , Modelos Animales de Enfermedad , Embolia/metabolismo , Hemo Oxigenasa (Desciclizante)/metabolismo , Miocitos Cardíacos/metabolismo , Factor 2 Relacionado con NF-E2/genética , Factor 2 Relacionado con NF-E2/metabolismo , Parvovirinae , Ratas Sprague-Dawley , ARN Mensajero/metabolismo , Transducción de Señal/efectos de los fármacos , Transfección
16.
Cell Physiol Biochem ; 41(4): 1675-1683, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28359050

RESUMEN

BACKGROUND/AIMS: Myocardial apoptosis is heavily implicated in the myocardial injury caused by coronary microembolization (CME), and toll-like receptor 4 (TLR4) is considered to be involved in this apoptotic cascade. Therefore, the present study was designed to investigate the role of TLR4/NF-κB signaling pathway regulated by TAK-242, a selective TLR4 signal transduction inhibitor, in the myocardial apoptosis after CME in rats. METHODS: Forty-five rats were randomized (random number) into three groups: sham, CME and CME + TAK-242 (n = 15 per group).CME was induced by injecting polyethylene microspheres (42µm) into the left ventricular except the sham group. CME + TAK-242 group was treated with TAK-242 (2mg/kg) via the tail vein 30 minutes before CME modeling. Cardiac function was evaluated 6 hours after operation. Tissue biopsy was stained with HBFP to measure the size of micro-infarction area. TUNEL staining was used to detect myocardial apoptosis. Western blot and qPCR were used to evaluate the expression of TLR4, MyD88, NF-κB p65, p-IκBα and Cleaved caspase-3. RESULTS: Cardiac function in the CME group and CME + TAK-242 group were significantly decreased compared with the sham group (P < 0.05) and the micro-infarction area, the apoptotic index, the expression of TLR4, NF-κB p65, p-IκBα and Cleaved caspase-3 were increased significantly (P < 0.05). Cardiac function in the CME + TAK-242 group was significantly improved compared with the CME group (P < 0.05) and the micro-infarction area, the apoptotic index, the expression of TLR4, MyD88, NF-κB p65, p-IκBα and Cleaved caspase-3 were decreased significantly (P < 0.05). CONCLUSIONS: TAK-242 can effectively improve CME-induced cardiac dysfunction by regulating TLR4/NF-κB signaling pathway and then reducing the myocardial apoptosis.


Asunto(s)
Apoptosis/efectos de los fármacos , Enfermedad Coronaria/metabolismo , Embolia/metabolismo , Miocardio/metabolismo , Transducción de Señal/efectos de los fármacos , Sulfonamidas/farmacología , Receptor Toll-Like 4/metabolismo , Factor de Transcripción ReIA/metabolismo , Animales , Caspasa 3/metabolismo , Enfermedad Coronaria/tratamiento farmacológico , Enfermedad Coronaria/patología , Embolia/tratamiento farmacológico , Embolia/patología , Masculino , Factor 88 de Diferenciación Mieloide/metabolismo , Miocardio/patología , Ratas , Ratas Sprague-Dawley
17.
Int J Mol Sci ; 17(3): 305, 2016 Feb 27.
Artículo en Inglés | MEDLINE | ID: mdl-26927091

RESUMEN

While inflammation has generally been regarded as a negative factor in stroke recovery, this viewpoint has recently been challenged by demonstrating that inflammation is a necessary and sufficient factor for regeneration in the zebrafish brain injury model. This close relationship with inflammation suggests that a re-examination of the immune system's role in strokes is necessary. We used a systems biology approach to investigate the role of immune-related functions via their interactions with other molecular functions in early cardioembolic stroke. Based on protein interaction models and on microarray data from the blood of stroke subjects and healthy controls, networks were constructed to delineate molecular interactions at four early stages (pre-stroke, 3 h, 5 h and 24 h after stroke onset) of cardioembolic stroke. A comparative analysis of functional networks identified interactions of immune-related functions with other molecular functions, including growth factors, neuro/hormone and housekeeping functions. These provide a potential pathomechanism for early stroke pathophysiology. In addition, several potential targets of miRNA and methylation regulations were derived based on basal level changes observed in the core networks and literature. The results provide a more comprehensive understanding of stroke progression mechanisms from an immune perspective and shed light on acute stroke treatments.


Asunto(s)
Enfermedad Coronaria/inmunología , Embolia/inmunología , Mapas de Interacción de Proteínas , Accidente Cerebrovascular/inmunología , Estudios de Casos y Controles , Enfermedad Coronaria/genética , Enfermedad Coronaria/metabolismo , Metilación de ADN , Embolia/genética , Embolia/metabolismo , Humanos , Inflamación/genética , Inflamación/inmunología , MicroARNs/genética , Unión Proteica , Accidente Cerebrovascular/genética , Accidente Cerebrovascular/metabolismo , Biología de Sistemas
18.
Cell Physiol Biochem ; 38(1): 207-19, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26784958

RESUMEN

BACKGROUND/AIMS: Phosphatase and tensin homolog deleted on chromosome ten (PTEN) has been recognized as a promoter of apoptosis in various tissues, and revealed to be up-regulated in circumstances of coronary microembolization (CME). However, whether this functional protein could be modified by pretreatment of atorvastatin in models of CME has not been disclosed yet. METHODS: Swine CME was induced by intra-coronary injection of inertia plastic microspheres (diameter 42 µm) into left anterior descending coronary, with or without pretreatment of atorvastatin or PTEN siRNA. Echocardiologic measurements, pathologic examination, TUNEL staining and western blotting were applied to assess their functional, morphological and molecular effects in CME. RESULTS: PTEN were aberrantly up-regulated in cardiomyocytes following CME, with both the mRNA and protein levels increased after CME modeling. Pretreatment with atorvastatin could attenuate the induction of PTEN. Furthermore, down-regulation of PTEN in vivo via siRNA was associated with an improved cardiac function, attenuated myocardial apoptosis, and concomitantly inhibited expressions of key proapoptotic proteins such as Bax, cleaved-caspase-3. Interestingly, atorvastatin could markedly attenuate PTEN expression and therefore partially reverse cardiac dysfunction and attenuate the apoptosis of the myocardium following CME. CONCLUSION: Modulation of PTEN was probably as a potential mechanism involved in the beneficial effects of pretreatment of atorvastatin to cardiac function and apoptosis in large animal models of CME.


Asunto(s)
Apoptosis/efectos de los fármacos , Atorvastatina/farmacología , Fosfohidrolasa PTEN/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Animales , Caspasa 3/metabolismo , Modelos Animales de Enfermedad , Regulación hacia Abajo , Ecocardiografía , Embolia/etiología , Embolia/metabolismo , Embolia/patología , Infarto del Miocardio/etiología , Infarto del Miocardio/metabolismo , Infarto del Miocardio/patología , Miocardio/metabolismo , Miocardio/patología , Fosfohidrolasa PTEN/antagonistas & inhibidores , Fosfohidrolasa PTEN/genética , Interferencia de ARN , ARN Interferente Pequeño/metabolismo , Transducción de Señal/efectos de los fármacos , Porcinos , Troponina I/sangre , Proteína X Asociada a bcl-2/metabolismo
19.
Can J Cardiol ; 31(10): 1272-81, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26095939

RESUMEN

BACKGROUND: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a membrane protein associated with apoptosis. Endoplasmic reticulum (ER) stress-induced apoptosis has been determined in several cardiovascular diseases. Mitogen-activated protein kinase (MAPK) signalling is involved in apoptosis. The aim of this study was to investigate whether LOX-1, ER stress, and MAPKs play a role in cardiomyocyte apoptosis after coronary microembolization (CME) and the exact mechanisms involved. METHODS: Thirty swine were randomized into the following groups (n = 5 per group): sham, CME, CME + LOX-1 small-interfering RNA (siRNA), CME + control siRNA, CME + JNK inhibitor, and CME + p38 inhibitor. The CME model was established by injecting microspheres into the left anterior descending (LAD) artery, whereas swine in the sham group received normal saline instead. Twelve hours after the sham operation or CME, cardiac function, serum c-troponin I level, microinfarcts, and apoptotic index were determined. Relative expression levels of LOX-1, ER stress markers (glucose-regulated protein 78 [GRP 78], C/EBP homologous protein [CHOP], and cleaved caspase-12), cleaved caspase-3, c-Jun NH2-terminal protein kinases (JNK), p38, and extracellular signal-related protein kinases (ERK1/2) were measured. RESULTS: CME induced cardiac dysfunction, microinfarction, increased serum c-troponin I levels, and cardiomyocyte apoptosis. Additionally, the expression of LOX-1, ER stress markers, and cleaved caspase-3, and the phosphorylation of JNK, p38, and ERK1/2 were all enhanced. LOX-1 siRNA inhibited these effects except the phosphorylation of ERK1/2. Pretreatment with a JNK inhibitor or a p38 inhibitor attenuated the expression of ER stress markers and apoptosis. CONCLUSIONS: Our results indicated that CME induced cardiomyocyte apoptosis through the LOX-1-dependent ER stress pathway, in which the phosphorylation of JNK and p38 were involved. This might provide a new approach for the prevention and treatment of CME.


Asunto(s)
Apoptosis , Embolia , Proteínas Quinasas JNK Activadas por Mitógenos/metabolismo , Infarto del Miocardio , Miocitos Cardíacos/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo , Animales , Circulación Coronaria/fisiología , Modelos Animales de Enfermedad , Embolia/complicaciones , Embolia/metabolismo , Retículo Endoplásmico/metabolismo , Estrés del Retículo Endoplásmico/fisiología , Pruebas de Función Cardíaca , Lipoproteínas LDL/metabolismo , Microesferas , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Infarto del Miocardio/diagnóstico , Infarto del Miocardio/etiología , Infarto del Miocardio/metabolismo , Porcinos , Troponina C/sangre
20.
Semin Thromb Hemost ; 41(2): 178-87, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25703519

RESUMEN

Anticoagulant treatment can be currently instituted with two different classes of drugs: the vitamin K antagonists (VKAs) and the newer, "novel" or non-vitamin K antagonist oral anticoagulant drugs (NOACs). The NOACs have several practical advantages over VKAs, such as the rapid onset/offset of action, the lower potential for food and drug interactions, and the predictable anticoagulant response. However, the VKAs currently have a broader spectrum of indications, a standardized monitoring test, and established reversal strategies. The NOACs emerged as alternative options for the prevention and treatment of venous thromboembolism and for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Nevertheless, there remain some populations for whom the VKAs remain the most appropriate anticoagulant drug. This article discusses the advantages and disadvantages of VKAs and NOACs.


Asunto(s)
Anticoagulantes/uso terapéutico , Embolia/prevención & control , Accidente Cerebrovascular/prevención & control , Vitamina K/antagonistas & inhibidores , Administración Oral , Anticoagulantes/farmacocinética , Embolia/metabolismo , Humanos , Accidente Cerebrovascular/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA